Continuous glucose monitoring identifies asymptomatic hypoglycemia and improves glycemic control in hepatic glycogen storage diseases
CGM consistently detected asymptomatic hypoglycemia in GSD patients, with adult cohorts spending up to 12% of time below 70 mg/dL despite normal spot checks. CGM-guided dietary titration improved Time in Range from 72% to 86% in gene therapy trials and reduced serum triglycerides and liver size.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Continuous glucose monitoring identifies asymptomatic hypoglycemia and improves glycemic control in hepatic glycogen storage diseases The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Continuous glucose monitoring identifies asymptomatic hypoglycemia and improves glycemic control in hepatic glycogen storage diseases
This conclusion is most relevant to: Patients with hepatic glycogen storage diseases (GSD Ia, Ib, III); 31 studies, N=323.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Continuous Glucose Monitoring in Glycogen Storage Diseases: A Systematic Review of Clinical Utility, Accuracy and Patient Outcomes. (Endocrinology, diabetes & metabolism, 2026) —
How It Works
The proposed biological pathway:
- ▸CGM provides continuous interstitial glucose readings
- ▸Detects rapid hypoglycemic excursions missed by intermittent monitoring
- ▸Guides dietary adjustments to stabilize glucose levels
- ▸Result: Improved Time in Range and reduced metabolic complications
Who Might Benefit
Evidence fit by population:
- ▸Patients with hepatic glycogen storage diseases (GSD Ia, Ib, III); 31 studies, N=323
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Sensor performance shows positive bias in the hypoglycemic range, potentially masking severe neuroglycopenia
- ▸CGM introduces 'alarm fatigue' from false-positive alerts, increasing patient burden
Frequently Asked Questions
What is the main benefit of CGM in GSD patients?▼
CGM provides superior sensitivity for detecting occult hypoglycemia that is missed by spot checks, allowing proactive stabilization of glucose levels.
Does CGM improve clinical outcomes in GSD?▼
Yes, CGM-guided dietary titration improved Time in Range (e.g., from 72% to 86% in gene therapy trials) and reduced serum triglycerides and liver size.
What are the downsides of using CGM in GSD?▼
CGM sensors have a positive bias in the hypoglycemic range, which can mask severe low glucose events, and patients may experience alarm fatigue from false-positive alerts.
Which GSD subtypes were studied?▼
The review predominantly included GSD subtypes Ia, Ib, and III.
References
- 1.Mohsenipour R, Abbasi F, Ghaderian MS, Dehkordi AK, Abdolahpour S, Akbari K. “Continuous Glucose Monitoring in Glycogen Storage Diseases: A Systematic Review of Clinical Utility, Accuracy and Patient Outcomes..” Endocrinology, diabetes & metabolism, 2026. PMID: 42394382 DOI: 10.1002/edm2.70274